Conducta médica en la prueba de puente del miocardio - Revisión de la literatura.

MARQUES, João Rodrigues Cordeiro; BICHOFE  Remes Anderson; KAISER, Karynn Teixeira; LUNARDI, Jennifer Cadoná; SOUZA, Marcos Flávio; CABALLERO,  Gabi Roseli Peralta; FRANCO, Solanche Molinas; SANGALETTE, Beatriz Sobrinho; TOLEDO, Gustavo Gustavo; VIOLATO, João Pedro Felicio; MARQUES, João Rodrigues Cordeiro; LUNARDI, Jennifer Cadoná; BUENO, Mariellen Nayara De Almeida; SA, Kim Fonseca Gomes; SOUZA,  Flávio Marcos; MARQUES, João Rodrigues Cordeiro; INÁCIO, Rodrigo Fabrizzio INÁCIO, Rodrigo Fabrizzio; PERPETUO, Fabio Luis PERPETUO, Fabio Luis; REGO, Antonine de Amorim REGO, Antonine de Amorim

Autores

INÁCIO, Rodrigo Fabrizzio UNIVERSIDADE CENTRAL DO PARAGUAI https://orcid.org/0000-0003-1464-0466
PERPETUO, Fabio Luis UNIVERSIDADE CENTRAL DO PARAGUAI https://orcid.org/0000-0002-6405-9226
REGO, Antonine de Amorim UNIVERSIDADE CENTRAL DO PARAGUAI https://orcid.org/0000-0001-5432-6717

Palavras-chave:

Insulina, Resistência Insulínica, Diagnóstico Diferencial, Experiência Clínica, Alteração Metabólica

Resumo

A resistência à insulina pode ser definida como uma resposta diminuída às ações biológicas da insulina, anormalidade que ocorre principalmente devido à ação inadequada da insulina nos tecidos periféricos, como tecido adiposo, muscular e hepático. Várias condições clínicas, como obesidade, diabetes mellitus, hipertensão, processos infecciosos e doenças endócrinas, estão correlacionadas com a resistência à insulina. A proporção de partículas pró-aterogênicas (contendo ApoB) para partículas antiaterogênicas (contendo ApoA1) pode estar associada a componentes da síndrome metabólica, como circunferência da cintura e pressão arterial aumentadas, HDL-c baixo e triglicerídeos elevados, além de ser um possível preditor cardiometabólico para aterosclerose. Este trabalho visa avaliar 2 casos clínicos, tendo os parâmetros feitos por análise laboratorial. A avaliação deu-se especificamente ao estado clínico dos pacientes, suportando a relação de ApoA1 e ApoB, dando-lhes índices de HDL e LDL, bem como alteração metabólica ou resistência à insulina. Assim, tendo em conta o índice de normalidade (≤ 0,75), foi aplicada a relação ApoB/ApoA1 a ambos os doentes. Os resultados levaram a uma nota de normalidade para o paciente 1 e alteração para o paciente 2, ou seja, apresentando resistência à insulina. Este trabalho visa colaborar com a exploração científica em exames laboratoriais, contribuindo para a experiência clínica uma melhor abordagem terapêutica para pacientes com resistência à insulina.

Biografia do Autor

INÁCIO, Rodrigo Fabrizzio, UNIVERSIDADE CENTRAL DO PARAGUAI

Académico do 7º período de Medicina, Mestre e Doutor em Ortopedia e Traumatologia, Biologia Celular e Estrutural, Investigador e Colaborador do Centro de Investigação da UCP.

PERPETUO, Fabio Luis, UNIVERSIDADE CENTRAL DO PARAGUAI

Académico do 7º período de Medicina, Especialista em Ortopedia e Traumatologia, Investigador e Colaborador do Núcleo de Investigação da UCP

REGO, Antonine de Amorim, UNIVERSIDADE CENTRAL DO PARAGUAI

Acadêmico do 7º período de Medicina, Colaborador do Núcleo de Investigação da Universidade Central do Paraguai

Referências

Ginsberg HN. Insulin Resistance and Cardiovascular Disease. J Clin Invest. 2000; 106(4):453-458.

Matthews DR. Insulin resistance and E-cell function – a clinical perspective. DiabObesMetab. 2001;3(sn):28-33.

Porte DJR, Kahn SE. Cell dysfunction and failure in type 2 diabetes potential mechanisms. Diabetes. 2001;50(1):160-163.

Yy J. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. EndocrMetab Immune Disord Drug Targets. 2007;7(1):65-74.

Mlinar B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta. 2007;375(1-2):20-35.

Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. End Rev. 1985;6(1):45-85.

Viner R, White B, Christie D. Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. Lancet. 2017;389(10085):2252-60.

Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in men. Obes Res. 1996;4(sn):583-600.

Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28(2):341-357.

Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G et al. Insulin, somatotropic and luteinizing hormone axes in lean and obese women with polycyistic ovary syndrome: Common and distinct features.J Clin EndocrinolMetab. 1996;81(8):2854-2864.

Barter PJ, Ballantyne CM, Carmena R, Cabezas MC, Chapman MJ et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty- -person/ten-country panel. J Intern Med.2006;259(3):247-258.

Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8(4):222-232.

Kappelle PJ, Gansevoort RT, Hillege JL, Wolffenbuttel BH, Dullaart RP. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria, and C-reactive protein.J Intern Med. 2011;269(2):232-242.

Retnakaran R et al. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. J Ped. 2006;148(2):176-182.

SavasErdeve S, Simsek E, Dallar Y, Biyikli Z. Utility of ApoB/ApoA1 Ratio for the Prediction of Cardiovascular Risk in Children with Metabolic Syndrome. Ind j Ped.2010;77(11): 1261–1265.

Brunzell JD.Dyslipidemia of the metabolic syndrome. In: Eckel R, ed. Obesity: Mechanisms and Clinical Management. New York: Lippincott Williams & Wilkins, 2003:378-398.

Bertolami, MC. Alterações do Metabolismo Lipídico no Paciente com Síndrome Metabólica.Rev Soc Cardiol Estado de São Paulo. 2004;4(5):51-60.

Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Internal Med.2004;255(2):188-205.

Neusa Forti N, Diament J. Apolipoproteínas B E A-I: fatores de risco cardiov cardiovascular ascular? Instituto do Coração HCFMUSP RevAssocMedBras 2007; 53(3): 276-Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.J Lip Res.1994;35(5):779-792.

Reaven GM, Chen V-D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Ver. 1988; 4(7):639-652.

Fujimoto WY, Abbate SL, Kahn SE, Boyko EJ, Hayashi T et al.The visceral adiposity syndrome in Japanese-American men. Obes Res.1994;2(4):364-371.

Tchernof A, Lamarche B, Prud’Homme D, Nadeau A, MoorjaniS, et al.The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diab Care. 1996;19(6):629–637.

Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003;52(1):172–179.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. Jama. 2002;287(3):356-359 Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis.1994; 106(2):241-253.

Haffner SM, Lehto S, Ronnemaa T,Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-234.

Mcneely MJ, Edwards KL, Marcovina SM, Dbrunzell JD, Gmotulsky A, Aaustin M. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis.2001;159(2):471-481.

Sniderman A, Shapiro S, Marpole D, et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density lipoproteins]. Proc Natl Acad Sci USA. 1980;77(1):604–608.

Himsworth H. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1936;1(sn):127-30.

The Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 11) NHLBI. J Am Med Assoc.

;269(sn):3015-3023.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79(1):8-15.

CamposH,MoyeLA,GlasserSP, Stampfer MJ, Saks FM.Low density lipoprotein size, pravastatin treatment, and coronary events. Jama.2001;286(12):1468-1474.

Reaven GM. Banting lecture 1988: role of insulin resistance in human disease.Diabetes. 1988;37(12):1595–1607.

Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest. 1974; 53(1):64-76.

Albrink MJ, Krauss RM, Lindgren FT, Von Der Groeben VD, Wood PDS. Intercorrelations among high density lipoproteins, obesity, and triglycerides in a normal population. J Am Oil Chem Soc.1980; 15(sn):1668-1678.

Laws A, Hoen HM, Selby N, Saad MF, Haffner SM, Howard BV. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study lIRAS Investigators. ArtherosclerThrombVasc Biol. 1997; 17(1):64-71.

Howard BV, Mayer-Davis EJ, Goff O, Zaccaro OJ, Laws A et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and Non-Hispanic Whites: the Insulin Resistance Atherosclerosis Study. Metabolism. 1998; 47(10):1174-1179.

Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28(6):613-628.

Kissebah AH, Alfarsi S, Evans OJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus.Diabetes. 1982; 31(3):217-225.

Ginsberg H, Grundy SM. Effect of caloric restriction on very low density lipoprotein triglyceride metabolism in subjects with diabetes mellitus. Diabetol. 1982; 23(sn):421-425.

Boden G. Fatty acids and insulin resistance. Diab Care. 1996; 19(4):394-395.

Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest. 1995; 96(3):1261 -1268.

Boden G, Chen X, Ruiz J, White N, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 1994; 93(6):2438-2446.

Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetes states. Diab Care. 1991; 14(9):839-855.

Taskinen M-R, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B- containing lipoproteins in NIDDM. Diabetes 1990; 39(9):1017-1027.

McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007 Apr 9;167(7):642-8.